Search research articles
Contact Us
Filters
Showing results (91-100 of 497) with videos related to
Page
of 50
Sort By:
Therapeutic Advances in Urology
|
July 11, 2015
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma
Elisa Zanardi, Elena Verzoni, Paolo Grassi, et al.
Targeted Oncology
|
April 16, 2018
The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review
Federico Nichetti, Antonio Marra, Francesca Corti, et al.
Tumori
|
August 27, 2019
Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma
Alice Indini, Lorenza Di Guardo, Carolina Cimminiello, et al.
American Journal of Clinical Oncology
|
September 26, 2013
Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors
Giuseppe Procopio, Paolo Grassi, Isabella Testa, et al.
Clinical Genitourinary Cancer
|
August 28, 2014
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data
Roberto Iacovelli, Matteo Santoni, Elena Verzoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2005
Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer?
Cristina Noberasco, Tommaso De Pas, Giuseppe Curigliano, et al.
Translational Oncology
|
June 29, 2012
Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen
Filippo Pietrantonio, Pamela Biondani, Filippo de Braud, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 22, 2015
Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis
Fausto Petrelli, Filippo Pietrantonio, Chiara Cremolini, et al.
Acta Oncologica (Stockholm, Sweden)
|
July 26, 2006
Successful chemotherapy and 90Y-DOTATOC in a patient with mediastinal highly aggressive neuroendocrine carcinoma
Nicola Fazio, Chiara Grana, Giuseppe Pelosi, et al.
Journal for Immunotherapy of Cancer
|
May 4, 2026
CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors
Giuseppe Nardo, Francesca Putti, Alice Indini, et al.
Page
of 50
Search research articles
Search
Showing results (91-100 of 497) with videos related to
Sort By:
Page
of 50
Therapeutic Advances in Urology
|
July 11, 2015
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma
Elisa Zanardi, Elena Verzoni, Paolo Grassi, et al.
Targeted Oncology
|
April 16, 2018
The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review
Federico Nichetti, Antonio Marra, Francesca Corti, et al.
Tumori
|
August 27, 2019
Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma
Alice Indini, Lorenza Di Guardo, Carolina Cimminiello, et al.
American Journal of Clinical Oncology
|
September 26, 2013
Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors
Giuseppe Procopio, Paolo Grassi, Isabella Testa, et al.
Clinical Genitourinary Cancer
|
August 28, 2014
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data
Roberto Iacovelli, Matteo Santoni, Elena Verzoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2005
Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer?
Cristina Noberasco, Tommaso De Pas, Giuseppe Curigliano, et al.
Translational Oncology
|
June 29, 2012
Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen
Filippo Pietrantonio, Pamela Biondani, Filippo de Braud, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 22, 2015
Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis
Fausto Petrelli, Filippo Pietrantonio, Chiara Cremolini, et al.
Acta Oncologica (Stockholm, Sweden)
|
July 26, 2006
Successful chemotherapy and 90Y-DOTATOC in a patient with mediastinal highly aggressive neuroendocrine carcinoma
Nicola Fazio, Chiara Grana, Giuseppe Pelosi, et al.
Journal for Immunotherapy of Cancer
|
May 4, 2026
CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors
Giuseppe Nardo, Francesca Putti, Alice Indini, et al.
Page
of 50